Looks interesting, similar theory to RG7388 which is currently being trialed Phase 2 in UK for PV patients intolerant to other treatments
This Phase 1 trial appears to be USA but worth following. Theory makes perfect common sense - inhibit the inhibitor that reduces our body’s defences against MPNs.
Thank you for posting this very interesting link Paul. Fabulous detailed research going on in our behalf.
Carolyn.
very interesting report. So much being done now for MPN's gives a lot of hope.
So can we understand if this drug will slow down the progression of PV to MF?
The clinical trials have started?
Do you know if RG7388 will slow down progression to.MF?
That is the hope. MPN patients tend to have promoted MDM2 which, as it rises, suppresses our anti cancer fighting p53. This opens door for faster progression.
I suspect our ‘near cure’ will be a combo of these drugs. I believe Peg and RG7388 are being trialed for stubborn (more aggressive?) cases.
Thank you for replying! One more question.. Have you understand if these inhibitors of MDM2 will work despite clonal mutation? I mean
. They may target a different path ,more unified??
Clinical Trial PV
tasquinimod in myelofibrosis (MF)
INCA033989 phase 1 clinical trial is recruiting patients 
